Health X Platform discloses voting results of 37th AGM

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • All seven agenda items at the 37th AGM passed with over 99.99% majority
  • 104 members participated via video conferencing out of 11,691 record shareholders
  • Composite Scheme of Arrangement approved to consolidate digital healthcare assets
  • Voting conducted solely through remote e-voting with no live meeting votes
powered bylight_fuzz_icon
52156670

*this image is generated using AI for illustrative purposes only.

Health X Platform Limited, formerly known as Sastasundar Ventures Limited, disclosed the detailed voting results of its 37th Annual General Meeting held on September 28, 2026. All seven agenda items were passed with requisite majority, as declared by the Chairman in compliance with SEBI (LODR) Regulations.

The meeting was conducted via Video Conferencing and Other Audio Visual Means, with 104 members participating in the proceedings. The primary focus was the approval of a Composite Scheme of Arrangement and Amalgamation involving Health X Platform, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited. This strategic restructuring aims to consolidate digital healthcare assets under a unified corporate structure.

Voting Results and Participation

The company filed the combined voting results and the Consolidated Scrutinizer's Report with BSE and NSE on September 29, 2026. A total of 11,691 shareholders were on record as of the cut-off date, September 21, 2026. Of these, 104 members attended via video conferencing, comprising 10 from the promoter group and 94 public shareholders. No physical attendance or proxy appointments were permitted due to the virtual format.

Voting was conducted exclusively through remote e-voting provided by MUFG Intime India Private Limited. No votes were cast during the live meeting session. The results indicate overwhelming support for all resolutions, with opposition votes remaining negligible across all items.

Resolution Type Item Status Votes For (%) Votes Against (%)
Ordinary Adopt Audited Financial Statements for FY26 Passed 99.9996 0.0004
Ordinary Re-appointment of Mrs. Abha Mittal Passed 99.9996 0.0004
Special Re-appointment of Mrs. Anjana Dikshit as Independent Director Passed 99.9996 0.0004
Special Approve overall borrowing limit under Section 180(1)(c) Passed 99.9996 0.0004
Special Authorize creation of mortgage or charge on assets Passed 99.9996 0.0004
Special Authorize loans, guarantees, security, and investments Passed 99.9996 0.0004
Special Authorize loans/guarantees/security under Section 185 Passed 99.9996 0.0004

Strategic Digital Assets Highlighted

During the address, Chairman B. L. Mittal emphasized the company's strengthened position through its key digital platforms. The company outlined its portfolio of digitally driven services designed to enhance healthcare access and supply chain efficiency:

  • SastaSundar App: A consumer-centric platform for seamless healthcare access.
  • RetailerShakti App: A B2B supply chain solution empowering pharmacies.
  • JitoHealth.com: A platform promoting generic medicines with AI-driven recommendations.
  • SastaSundar Health & Happiness Podcast: An initiative to combat misinformation with trusted information.

Composite Scheme Details

The Board approved the composite scheme on June 10, 2026, following recommendations from the Committee of Independent Directors and the Audit Committee. The arrangement is subject to approvals from stock exchanges, SEBI, NCLT, RBI, and respective shareholders and creditors. NOC applications have been filed with the stock exchanges and RBI.

Governance and Compliance

The meeting was chaired by Mr. B. L. Mittal, with all directors and key managerial personnel present. The statutory auditors' report contained no qualifications, reservations, or adverse remarks. Similarly, the secretarial audit report was clean. The scrutinizer's report, prepared by MKB & Associates, confirmed that all votes were valid and that the resolutions were passed in accordance with the Companies Act, 2013.

Historical Stock Returns for Health X Platform

1 Day5 Days1 Month6 Months1 Year5 Years
-1.76%-4.29%-6.49%+3.30%-10.08%0.0%

What is the expected timeline for NCLT and SEBI approvals regarding the composite scheme of arrangement?

How will the consolidation of Microsec Resources and Innogrow Technologies impact Health X Platform's operational synergies and cost structure?

What specific AI-driven features are planned for JitoHealth.com to enhance its competitive edge in the generic medicine market?

Health X Platform files FY26 BRSR with BSE and NSE exchanges

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Health X Platform filed its FY26 BRSR with BSE and NSE on September 4, 2026
  • Paid-up capital stands at ₹3181.05 lakhs with consolidated reporting basis
  • Wholesale pharmaceutical trading contributes 98.80% of total turnover
  • No assurance provider was engaged for the sustainability report
powered bylight_fuzz_icon
50062349

*this image is generated using AI for illustrative purposes only.

Health X Platform Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the Bombay Stock Exchange and National Stock Exchange on September 4, 2026. The filing provides consolidated disclosures on the company’s operational and sustainability metrics.

The report was filed pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is also available on the company’s website. Pratap Singh, Company Secretary and Compliance Officer, signed the document.

General Disclosures

The listed entity, formerly known as Sastasundar Ventures Limited, was incorporated on June 6, 1989. Its registered and corporate office is located in Kolkata. The paid-up capital stands at ₹3181.05 lakhs. The reporting boundary for this BRSR is on a consolidated basis. No assurance provider was engaged for this report.

Detail Information
CIN L65993WB1989PLC047002
Paid-up Capital ₹3181.05 lakhs
Reporting Basis Consolidated
Assurance Provider Not Applicable

Business Activities

Wholesale trading of pharmaceutical and OTC products accounts for 98.80% of the entity’s turnover. Other financial service activities contribute a negligible 0.002%. The company operates under NIC codes 46497 and 46901 for its primary wholesale activities.

Activity % of Turnover
Wholesale of pharmaceutical/medical goods 98.80%
Other Financial Service activities 0.002%

Historical Stock Returns for Health X Platform

1 Day5 Days1 Month6 Months1 Year5 Years
-1.76%-4.29%-6.49%+3.30%-10.08%0.0%

How might the lack of an independent assurance provider for this BRSR impact investor confidence in Health X's sustainability claims compared to peers?

Given that 98.8% of turnover comes from pharmaceutical wholesale, what specific sustainability risks related to supply chain logistics or regulatory compliance is the company prioritizing in FY27?

Will Health X Platform initiate a strategic pivot to diversify its revenue streams beyond wholesale trading to mitigate concentration risk in the coming fiscal years?

More News on Health X Platform

1 Year Returns:-10.08%